Human Beta-defensin 1 in Vitiligo

Cairo University (CU)

Status: Unknown

Conditions: Vitiligo

Treatments: Other: skin biopsy before and after NB-UVB phototherapy

Study type: Interventional

Funder types: Other

Identifiers

NCT03832751

Dermatology 12

Details and patient eligibility

About

There is a need to know the role of human beta defensin-1 in vitiligo pathogenesis and the probability of finding newer and effective therapy for vitiligo in the future.

Enrollment: 25 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients with non-segmental vitiligo.
• Both genders.
• Age more than 18 years old.
• New cases or cases not receiving any treatment for at least 3 months prior to the study.

Exclusion criteria

• Universal or segmental vitiligo.
• Any contraindication to phototherapy treatment.
• History of autoimmune diseases or other systemic diseases.
• Any other skin disease.

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

25 participants in 2 patient groups

vitiligo patients

Experimental group

Description:

Tissue levels of human beta-defensin 1 in vitiligo patients before and after NB-UVB phototherapy

Treatment:

Other: skin biopsy before and after NB-UVB phototherapy

Healthy controls

Active Comparator group

Description:

Tissue levels of human beta-defensin 1 in healthy controls

Treatment:

Other: skin biopsy before and after NB-UVB phototherapy